Literature DB >> 21769747

The evolving concept of Treatment- Resistant Schizophrenia.

Javier Quintero1, Eduardo Barbudo del Cura, Maria I López-Ibor, Juan J López-Ibor.   

Abstract

Schizophrenia is a chronic disease of body and mind that affects 1% of the population. The existence of the person with schizophrenia should be understood, at least, from two perspectives: one considering the integration of the individual into the social community, another understanding that there is a patient with a medical problem treatable with medications and psychotherapies. There is a large group of patients with 'treatment-resistant schizophrenia," that is, cases in which a minimum degree of remission with conventional treatments is not obtained. These cases have pointed to the fact that even today we still lack an integrative treatment model obtained through the assembling of specific interventions with verifiable effectiveness. The concept of treatment-resistant schizophrenia should have evolved in accordance with the advancing of the currently available knowledge and therapeutic resources. Why hasn't this happened? This article reviews the history of the concept of "resistance" to account for such failure and proposes a methodological approach to overcome this stagnation.

Entities:  

Mesh:

Year:  2011        PMID: 21769747

Source DB:  PubMed          Journal:  Actas Esp Psiquiatr        ISSN: 1139-9287            Impact factor:   1.196


  2 in total

1.  Accessing Gene Expression in Treatment-Resistant Schizophrenia.

Authors:  Patricia N Moretti; Vanessa K Ota; Eduardo S Gouvea; Mariana Pedrini; Marcos L Santoro; Fernanda Talarico; Leticia M Spindola; Carolina Muniz Carvalho; Cristiano Noto; Gabriela Xavier; Elisa Brietzke; Ary Gadelha; Rodrigo Bressan; Jair Mari; Sintia Belangero
Journal:  Mol Neurobiol       Date:  2018-01-26       Impact factor: 5.590

Review 2.  Recent Discussions on Dopamine Supersensitivity Psychosis: Eight Points to Consider When Diagnosing Treatment-Resistant Schizophrenia.

Authors:  Nobuhisa Kanahara; Hiroshi Kimura; Yasunori Oda; Fumiaki Ito; Masaomi Iyo
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.708

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.